Supernus Pharmaceuticals Inc (SUPN)

Debt-to-capital ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	0	0	400,382	379,252	374,788	370,383	366,038	361,751	357,521	353,349	349,232
Total stockholders’ equity	US$ in thousands	1,035,730	1,007,150	957,454	929,166	921,516	912,191	919,908	912,150	886,204	852,798	841,434	828,446	815,851	810,468	785,579	754,444	744,858	708,879	665,974	613,383
Debt-to-capital ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.33	0.32	0.32	0.32	0.33	0.33	0.34	0.35	0.36

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $1,035,730K)
= 0.00

The debt-to-capital ratio of Supernus Pharmaceuticals Inc has shown a declining trend from 0.36 as of March 31, 2020, to 0.32 as of December 31, 2021. This indicates that the company has been reducing its reliance on debt in its capital structure over this period. The ratio remained stable at 0.32 in the subsequent quarters up to March 31, 2022.

Starting from June 30, 2022, the debt-to-capital ratio dropped significantly to 0.00, and this trend continued through the subsequent quarters up to December 31, 2024. A debt-to-capital ratio of 0.00 suggests that the company had no debt in its capital structure during this period, indicating a strong financial position and potentially lower financial risk due to reduced interest payment obligations.

In conclusion, the declining trend in the debt-to-capital ratio up to March 31, 2022, followed by a sudden drop to 0.00 from June 30, 2022, and remaining at 0.00 thereafter indicates Supernus Pharmaceuticals Inc's ability to effectively manage its debt levels and maintain a healthy capital structure.